Academic Journal
Pathophysiological mechanisms and therapeutic potential of E-selectin in pulmonary arterial hypertension.
| Τίτλος: | Pathophysiological mechanisms and therapeutic potential of E-selectin in pulmonary arterial hypertension. |
|---|---|
| Συγγραφείς: | Lama E; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Wang Y; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Wu J; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Ma Q; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Chen H; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Wang Y; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Yang Y; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China.; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China., Liu C; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Ni X; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China., Zhou Z; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Key Laboratory of Biological Targeted Therapy, Huazhong University of Science and Technology, Ministry of Education, Wuhan, Hubei, China. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Jul 10; Vol. 17, pp. 1754940. Date of Electronic Publication: 2026 Jul 10 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | E-Selectin*/metabolism , E-Selectin*/genetics , Pulmonary Arterial Hypertension*/drug therapy , Pulmonary Arterial Hypertension*/metabolism , Pulmonary Arterial Hypertension*/physiopathology, Humans ; Animals ; Vascular Remodeling ; Biomarkers ; Pulmonary Artery |
| Περίληψη: | Pulmonary arterial hypertension (PAH) is a life-threatening pulmonary vascular disease characterized by progressive obstructive remodeling of the small pulmonary arteries. Its pathophysiological core involves perivascular inflammation, endothelial dysfunction, abnormal vascular wall proliferation and in situ thrombosis, arising from interactions between genetic susceptibility and environmental factors. Recent studies have demonstrated the central role of chronic inflammation in the development and progression of PAH. E-selectin, an endothelial-specific adhesion molecule, plays a critical role in mediating the initial adhesion and migration of leukocytes and in triggering the inflammatory cascade. Clinical and experimental studies have demonstrated that E-selectin levels are significantly elevated in both the circulation and local lung tissues of patients with PAH, and that these levels are positively correlated with disease severity. Although observational data have not yet directly established a causal relationship, the combination of its well-recognized proinflammatory properties suggests that E-selectin may function not only as an inflammatory marker but also as a potential key mediator driving pulmonary vascular inflammation and remodeling. This review systematically discusses the biological characteristics of E-selectin and its expression regulation in PAH, further explores the molecular and cellular mechanisms by which it contributes to vascular remodeling, and focuses on potential therapeutic strategies targeting E-selectin, with the aim of providing a new perspective for precision anti-inflammatory treatment in PAH. (Copyright © 2026 Lama, Wang, Wu, Ma, Chen, Wang, Yang, Liu, Ni and Zhou.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Clin Genet. 2001 Jan;59(1):58-64. (PMID: 11168027) Inflammation. 1994 Aug;18(4):389-98. (PMID: 7527013) Sci Rep. 2025 Dec 10;16(1):1589. (PMID: 41372353) J Immunol. 2000 Mar 15;164(6):3292-300. (PMID: 10706722) J Surg Res. 1997 Dec;73(2):107-12. (PMID: 9441802) Science. 1997 Oct 24;278(5338):687-9. (PMID: 9381178) Intensive Care Med. 2011 Aug;37(8):1368-77. (PMID: 21626431) Biosens Bioelectron. 2023 Feb 15;222:114921. (PMID: 36521205) Eur Heart J. 2024 Jun 1;45(21):1937-1952. (PMID: 38416633) Microvasc Res. 2016 Jul;106:44-56. (PMID: 27033411) Thromb Haemost. 2003 Dec;90(6):1141-9. (PMID: 14652649) Hum Mol Genet. 1994 Nov;3(11):1935-7. (PMID: 7533025) J Am Coll Cardiol. 2019 May 28;73(20):2567-2580. (PMID: 31118151) Inflammation. 2018 Mar;41(2):555-561. (PMID: 29218606) Adv Ther. 2025 May;42(5):2298-2313. (PMID: 40100308) Blood. 2017 Nov 9;130(19):2101-2110. (PMID: 28811304) Arthritis Rheumatol. 2022 Jul;74(7):1132-1138. (PMID: 35174669) ACS Appl Nano Mater. 2023 Jan 27;6(2):1315-1324. (PMID: 37789828) Blood Rev. 2024 May;65:101184. (PMID: 38493006) Nature. 1992 Nov 12;360(6400):127-34. (PMID: 1436090) Rheumatology (Oxford). 2025 Sep 1;64(9):4968-4975. (PMID: 40341469) Curr Opin Cardiol. 2007 Jul;22(4):316-20. (PMID: 17556884) J Autoimmun. 2020 Aug;112:102486. (PMID: 32482487) J Am Coll Cardiol. 2019 Sep 24;74(12):1594-1607. (PMID: 31537270) Hypertension. 2023 Aug;80(8):1784-1794. (PMID: 37313754) Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16093-8. (PMID: 12456881) Blood. 2007 Dec 1;110(12):3891-9. (PMID: 17699745) Lung. 2006 Sep-Oct;184(5):259-66. (PMID: 17235725) Am J Respir Crit Care Med. 2012 Aug 1;186(3):261-72. (PMID: 22679007) Eur Respir J. 2010 Dec;36(6):1284-93. (PMID: 20413531) Immunity. 2007 Jun;26(6):773-83. (PMID: 17543554) Blood. 1996 Nov 1;88(9):3259-87. (PMID: 8896391) Cell. 1997 Oct 17;91(2):231-41. (PMID: 9346240) Int J Mol Sci. 2024 Aug 01;25(15):. (PMID: 39125996) Hum Genet. 1996 Jan;97(1):15-20. (PMID: 8557254) Eur Respir J. 2024 Oct 31;64(4):. (PMID: 39209474) Nat Rev Cardiol. 2021 Sep;18(9):666-682. (PMID: 33958774) Nat Immunol. 2023 Dec;24(12):2021-2031. (PMID: 37903858) Adv Healthc Mater. 2024 Jun;13(15):e2400113. (PMID: 38412500) FASEB J. 1995 Jul;9(10):899-909. (PMID: 7542214) Arterioscler Thromb Vasc Biol. 2022 May;42(5):613-631. (PMID: 35387479) Am J Pathol. 1994 Feb;144(2):275-85. (PMID: 7508683) Toxicology. 2025 Feb;511:154046. (PMID: 39778856) J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54. (PMID: 19555858) J Clin Invest. 1998 Oct 15;102(8):1526-33. (PMID: 9788965) Science. 1989 Mar 3;243(4895):1160-5. (PMID: 2466335) Crit Care. 2003 Apr;7(2):130-8. (PMID: 12720559) Eur Respir J. 2005 Dec;26(6):1110-8. (PMID: 16319344) Stroke. 2000 Dec;31(12):3047-53. (PMID: 11108771) Science. 2008 Nov 14;322(5904):1101-4. (PMID: 19008446) J Exp Med. 2008 Sep 29;205(10):2339-47. (PMID: 18794338) Annu Rev Cell Dev Biol. 2010;26:363-96. (PMID: 19575676) Eur J Clin Invest. 2018 Jan;48(1):. (PMID: 29178542) Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):783-8. (PMID: 12649084) J Liposome Res. 2026 Mar 18;:1-13. (PMID: 41848579) Am J Respir Crit Care Med. 2022 Sep 1;206(5):532-534. (PMID: 35704289) Eur Respir J. 2023 Jan 6;61(1):. (PMID: 36028254) Cell Death Discov. 2023 Feb 25;9(1):78. (PMID: 36841823) Nat Commun. 2025 Mar 10;16(1):2356. (PMID: 40064845) Am J Respir Crit Care Med. 2015 Oct 15;192(8):983-97. (PMID: 26203495) Blood. 2010 Apr 15;115(15):3118-27. (PMID: 20167705) Eur Respir J. 2019 Jan 24;53(1):. (PMID: 30545970) J Heart Lung Transplant. 2025 Jan;44(1):1-10. (PMID: 39369970) Adv Sci (Weinh). 2025 Aug;12(31):e04397. (PMID: 40492585) Fundam Clin Pharmacol. 2013 Jun;27(3):271-8. (PMID: 22251079) Eur Respir J. 2003 Aug;22(2):358-63. (PMID: 12952274) Microcirculation. 1998;5(2-3):153-71. (PMID: 9789256) Eur Respir Rev. 2023 Dec 20;32(170):. (PMID: 38123231) Biochim Biophys Acta. 2000 Jun 2;1497(1):1-10. (PMID: 10838154) Chest. 2025 Jan;167(1):16-18. (PMID: 39794066) J Hum Hypertens. 2006 Jul;20(7):537-9. (PMID: 16625236) Cureus. 2024 Jun 9;16(6):e61996. (PMID: 38983984) Adv Ther. 2022 Jan;39(1):796-810. (PMID: 34727317) Front Med (Lausanne). 2018 Aug 03;5:217. (PMID: 30131961) Ann Biomed Eng. 2002 Sep;30(8):987-1001. (PMID: 12449760) Science. 1990 Nov 23;250(4984):1130-2. (PMID: 1701274) Mol Ther Nucleic Acids. 2021 Sep 20;26:678-693. (PMID: 34703652) Immunity. 2007 Apr;26(4):477-489. (PMID: 17442598) Front Immunol. 2024 Jul 19;15:1401399. (PMID: 39100681) Eur Heart J. 2022 Oct 11;43(38):3618-3731. (PMID: 36017548) Eur Respir J. 2021 Sep 2;58(3):. (PMID: 33509961) J Exp Med. 1994 Feb 1;179(2):503-12. (PMID: 7507507) Cell Mol Immunol. 2021 Feb;18(2):374-384. (PMID: 33420357) Methodist Debakey Cardiovasc J. 2021 Jul 01;17(2):106-114. (PMID: 34326930) Front Immunol. 2022 Feb 21;13:773291. (PMID: 35265067) Heart Lung Circ. 2022 Jul;31(7):934-943. (PMID: 35361533) J Surg Res. 2003 Jan;109(1):1-7. (PMID: 12591228) J Immunol. 2000 Apr 15;164(8):4348-58. (PMID: 10754335) Am J Pathol. 2006 Feb;168(2):659-69. (PMID: 16436679) Yale J Biol Med. 2012 Jun;85(2):167-85. (PMID: 22737047) Blood. 1998 May 15;91(10):3527-61. (PMID: 9572988) BMJ. 2018 Mar 14;360:j5492. (PMID: 29540357) Cells. 2020 Oct 22;9(11):. (PMID: 33105588) J Hypertens. 2004 Feb;22(2):305-11. (PMID: 15076188) Blood. 2016 Aug 11;128(6):753-62. (PMID: 27354721) Trends Cardiovasc Med. 1995 Jul-Aug;5(4):149-57. (PMID: 21232252) Lancet Respir Med. 2016 Apr;4(4):306-22. (PMID: 26975810) Mol Cell Biol. 1993 Jun;13(6):3301-10. (PMID: 8497253) |
| Contributed Indexing: | Keywords: E-selectin; endothelial cell dysfunction; inflammatory response; pulmonary arterial hypertension; therapeutic targets; vascular remodeling |
| Substance Nomenclature: | 0 (E-Selectin) 0 (Biomarkers) |
| Entry Date(s): | Date Created: 20260725 Date Completed: 20260725 Latest Revision: 20260813 |
| Update Code: | 20260814 |
| PubMed Central ID: | PMC13395753 |
| DOI: | 10.3389/fimmu.2026.1754940 |
| PMID: | 42500676 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!